Identifying patients who may benefit from capivasertib after progression on first-line ET (i.e., those whose cancer has ≥1 PIK3CA, AKT1, and/or PTEN alterations), will provide an opportunity to achieve glycemic control, if needed, before initiating capivasertib. Here, AKT1 is linked to cancer.